STUDY OBJECTIVE: Data from randomized controlled trials support a mortality benefit with ticagrelor versus clopidogrel among patients with acute myocardial infarction (AMI). Many healthcare providers preferentially treat patients with AMI with ticagrelor. The goal of this study was to determine the association between out-of-pocket drug costs and ticagrelor continuation compared with switching to clopidogrel among patients hospitalized for AMI, following a pharmacist-led discussion on outpatient co-payment costs for ticagrelor. DESIGN: Retrospective cohort study. SETTING: A tertiary care academic medical center. PATIENTS: Patients hospitalized with AMI between February 15, 2015 and January 23, 2017, who were loaded with ticagrelor on presentation. MAIN RESULTS: Of 143 patients with AMI loaded with ticagrelor, 70 (49%) switched to clopidogrel after cost discussion. The median monthly ticagrelor co-payment was $268.29 (interquartile range [IQR] $45-$350) for switchers, versus $18 (IQR $6-$24) for non-switchers (p<0.001). Patients with co-payments of $100/month or more were 3.4 times more likely to switch to clopidogrel (relative risk 3.41, 95% confidence interval 2.12 to 5.47), compared with patients with co-payments of less than $100/month. CONCLUSIONS: Following a discussion of outpatient costs, half of patients with AMI switched from ticagrelor to clopidogrel when given the choice.
STUDY OBJECTIVE: Data from randomized controlled trials support a mortality benefit with ticagrelor versus clopidogrel among patients with acute myocardial infarction (AMI). Many healthcare providers preferentially treat patients with AMI with ticagrelor. The goal of this study was to determine the association between out-of-pocket drug costs and ticagrelor continuation compared with switching to clopidogrel among patients hospitalized for AMI, following a pharmacist-led discussion on outpatient co-payment costs for ticagrelor. DESIGN: Retrospective cohort study. SETTING: A tertiary care academic medical center. PATIENTS: Patients hospitalized with AMI between February 15, 2015 and January 23, 2017, who were loaded with ticagrelor on presentation. MAIN RESULTS: Of 143 patients with AMI loaded with ticagrelor, 70 (49%) switched to clopidogrel after cost discussion. The median monthly ticagrelor co-payment was $268.29 (interquartile range [IQR] $45-$350) for switchers, versus $18 (IQR $6-$24) for non-switchers (p<0.001). Patients with co-payments of $100/month or more were 3.4 times more likely to switch to clopidogrel (relative risk 3.41, 95% confidence interval 2.12 to 5.47), compared with patients with co-payments of less than $100/month. CONCLUSIONS: Following a discussion of outpatient costs, half of patients with AMI switched from ticagrelor to clopidogrel when given the choice.
Authors: Thomas M Maddox; Nancy M Albert; William B Borden; Lesley H Curtis; T Bruce Ferguson; David P Kao; Gregory M Marcus; Eric D Peterson; Rita Redberg; John S Rumsfeld; Nilay D Shah; James E Tcheng Journal: Circulation Date: 2017-03-02 Impact factor: 29.690
Authors: Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith Journal: J Am Coll Cardiol Date: 2016-03-29 Impact factor: 24.094
Authors: Niteesh K Choudhry; Jerry Avorn; Robert J Glynn; Elliott M Antman; Sebastian Schneeweiss; Michele Toscano; Lonny Reisman; Joaquim Fernandes; Claire Spettell; Joy L Lee; Raisa Levin; Troyen Brennan; William H Shrank Journal: N Engl J Med Date: 2011-11-14 Impact factor: 91.245
Authors: Ali Pourdjabbar; Benjamin Hibbert; Aun-Yeong Chong; Michel R Le May; Marino Labinaz; Trevor Simard; F Daniel Ramirez; Peter Lugomirski; Ronnen Maze; Michael Froeschl; Christopher Glover; Alexander Dick; Jean-Francois Marquis; Jordan Bernick; George Wells; Derek Y F So Journal: Thromb Haemost Date: 2016-10-20 Impact factor: 5.249
Authors: Dawn Stacey; Carol L Bennett; Michael J Barry; Nananda F Col; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; France Légaré; Richard Thomson Journal: Cochrane Database Syst Rev Date: 2011-10-05
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: W Frank Peacock; Michael C Kontos; Ezra Amsterdam; Christopher P Cannon; Deborah Diercks; Lee Garvey; Louis Graff; DaJuanicia Holmes; Kay Styer Holmes; James McCord; Kristin Newby; Matthew Roe; Shahriar Dadkhah; Angela Siler-Fisher; Michael Ross Journal: Crit Pathw Cardiol Date: 2013-09
Authors: Dhruv S Kazi; Alan M Garber; Rashmee U Shah; R Adams Dudley; Matthew W Mell; Ceron Rhee; Solomon Moshkevich; Derek B Boothroyd; Douglas K Owens; Mark A Hlatky Journal: Ann Intern Med Date: 2014-02-18 Impact factor: 25.391